1Année·

FDA Approves LEQEMBI® IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

$BIIB (+0,14 %) --> More sales coming?

https://investors.biogen.com/news-releases/news-release-details/fda-approves-leqembir-lecanemab-irmb-iv-maintenance-dosing

investors.biogen.comAccess Denied

3

Participez à la conversation

S'inscrire Connexion